LEVIN ARTHUR A 4

What Happened
Arthur A. Levin, a director of Stoke Therapeutics, was granted a derivative award for 17,786 shares on June 3, 2026. The reported acquisition shows a $0.00 price (no cash paid) and is classified as an award/grant (transaction code A). This was not a sale or open‑market purchase — it is a compensation/equity award that may convert to common shares if vesting conditions are met.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-05 (filed timely within standard reporting window).
• Awarded shares: 17,786 derivative shares; reported acquisition price: $0.00.
• Post-transaction ownership: Not disclosed in the provided filing.
• Footnote: The award vests in full on the earlier of (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of stockholders, subject to Levin’s continued service (per filing footnote).
• Transaction code: A (award/grant of derivative securities). No 10b5-1 plan, tax‑withholding, or cashless exercise noted in the filing.

Context
This is a grant of derivative equity (likely stock options or RSUs as reported on the Form 4) that will vest in the future; it does not represent an immediate sale or cash inflow. Such awards are routine components of director compensation and do not by themselves indicate a buy or sell signal.